<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000598.v2.p2" parentStudy="phs000598.v2.p2" createDate="2013-10-22" modDate="2013-10-22">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Adam Bass</td><td>Dana-Farber Cancer Institute, Boston, MA; Broad Institute, Cambridge MA; Brigham and Women&#39;s 			Hospital, Boston, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Exome Sequencing of Esophageal Adenocarcinoma</StudyNameEntrez>
	<StudyNameReportPage>Exome Sequencing of Esophageal Adenocarcinoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
		<StudyType>Tumor vs. Matched-Normal</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. When coupled to the five-year survival rate of only 15% for this disease, identification of new therapeutic targets for EAC is of great importance. Here, we analyze the mutational spectra identified from the whole genome sequencing of 16 EACs and complete exome sequencing of 149 EAC tumors and matched germline samples. We identify a novel mutation signature marked by high prevalence of A to C transversions at AA*(N) trinucleotides. Notably, the development of EAC is preceded by pathologic intestinal metaplasia of the lower esophagus, Barrett&#39;s esophagus, itself a response to injury from gastric-esophageal reflux disease (GERD). Thus, we hypothesize to represent these AA*(N) mutations to a novel signature of GERD-induced mutagenesis. Analysis of the exome data identified 26 genes subject to statistically significant recurrent mutation. Of these 26 genes, only TP53, CDKN2A, SMAD4, and PIK3CA had been previously implicated in EAC. Novel mutations include those targeting chromatin modifying factors and novel candidate contributors to EAC: SPG20, TLR4, ELMO1 and DOCK2. Of these, ELMO1 and DOCK2 are notably direct dimerization partners that act to activate Rac1 to enhance cellular invasiveness, thus generating new hypotheses about the potential for the Rac1 pathway to be a novel target for therapy of EAC.</p> <p>"Reprinted from &#39;Unraveling the mutational complexity of esophageal adenocarcinoma&#39;, with permission from Nature Genetics."</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Austin M. Dulak, Petar Stojanov, Shouyong Peng, Michael S. Lawrence, 			Cameron Fox, Chip Stewart, Santhoshi Bandla, Yu Imamura1, Steven E. Schumacher, 			Erica Shefler, Aaron McKenna, Kristian Cibulskis, Andrey Sivachenko, Scott L. Carter, 			Gordon Saksena, Douglas Voet, Alex H. Ramos, Daniel Auclair, Kristin Thompson, Carrie 			Sougnez, Robert C. Onofrio, Candace Guiducci, Rameen Beroukhim1, David Zhou, 			Lin Lin, Jules Lin, Rishindra Reddy, Andrew Chang, James D. Luketich, Arjun Pennathur, 			Shuji Ogino1, Todd R. Golub1, Matthew Meyerson, Stacey B. Gabriel, 			Eric S. Lander, David G. Beer, Tony E. Godfrey, Gad Getz, Adam J. Bass" title="Unraveling the mutational complexity of esophageal adenocarcinoma" journal="Nature Genetics, Accepted"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Esophageal Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Adam Bass</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA; Broad Institute, Cambridge MA; Brigham and Women&#39;s 			Hospital, Boston, MA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-HEC" longName="Disease-Specific (Human Esophageal Cancer)"/>
		<ConsentGroup groupNum="2" shortName="DS-CA" longName="Disease-Specific (Cancer)"/>
		<ConsentGroup groupNum="3" shortName="DS-CA-MDS" longName="Disease-Specific (Cancer, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000598.v2.p2_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000598.v2.p2
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000598.v2.p2" FileName="ESOPHAGEAL_ADENOCARCINOMA_NHGRI_DUC_7_11_2012.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Human Esophageal Cancer)</ConsentName>
        <ConsentAbbrev>DS-HEC</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Human Esophageal Cancer.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Cancer)</ConsentName>
        <ConsentAbbrev>DS-CA</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="3">
        <ConsentName>Disease-Specific (Cancer, MDS)</ConsentName>
        <ConsentAbbrev>DS-CA-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
